Lb Pharmaceuticals (LBRX) Total Non-Current Liabilities (2024 - 2026)

Lb Pharmaceuticals' Total Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $13.6 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $13.6 million; the TTM figure through Mar 2026 stood at $13.6 million (changed N/A YoY), while the FY2025 annual figure was $10.3 million, down 9.22% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $13.6 million, up from $10.3 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $13.6 million in Q1 2026, with the low at $9.6 million in Q3 2025.
• The 3-year median for Total Non-Current Liabilities is $10.8 million (2024), against an average of $11.2 million.
• Peak annual rise in Total Non-Current Liabilities reached 9.22% in 2025, while the deepest fall reached 9.22% in 2025.
• Lb Pharmaceuticals' Total Non-Current Liabilities stood at $11.3 million in 2024, then decreased by 9.22% to $10.3 million in 2025, then surged by 32.73% to $13.6 million in 2026.
• Business Quant data shows LBRX's Total Non-Current Liabilities at $13.6 million in Q1 2026, $10.3 million in Q4 2025, and $9.6 million in Q3 2025.